Regeneron And Lilly Are Back With Better COVID-19 Antibody Data – But Still Face Medical Skepticism

New Variants Also Make SARS-CoV2 A Moving Target

 
• By Andrew McConaghie
  
Hospital Covid patient
New data suggests the antibody therapies can have a big impact in preventing infection, or preventing at-risk individuals being hospitalized with severe COVID-19. • Source: Getty Images
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip